GRAIL (NASDAQ:GRAL) Insider Sells $1,152,528.47 in Stock

GRAIL, Inc. (NASDAQ:GRAL) insider Andrew Partridge sold 7,873 shares of the stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $146.39, for a total value of $1,152,528.47. Following the transaction, the insider owned 155,865 shares in the company, valued at $22,817,077.35. The trade was a 4.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

GRAIL Stock Up 6.0%

NASDAQ:GRAL opened at $140.58 on Friday. GRAIL, Inc. has a twelve month low of $41.50 and a twelve month high of $166.48. The company has a fifty day moving average of $92.37 and a 200-day moving average of $72.07. The firm has a market capitalization of $6.28 billion, a P/E ratio of -14.42 and a beta of 2.83.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, beating the consensus estimate of ($2.66) by $0.10. The firm had revenue of $44.69 million during the quarter, compared to the consensus estimate of $42.39 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. On average, analysts anticipate that GRAIL, Inc. will post -10.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on GRAL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research note on Friday, July 17th. Canaccord Genuity Group lifted their price target on shares of GRAIL from $80.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 28th. Royal Bank Of Canada assumed coverage on shares of GRAIL in a report on Thursday, September 17th. They set a “sector perform” rating and a $84.00 price objective on the stock. TD Cowen reaffirmed a “buy” rating on shares of GRAIL in a research note on Thursday, September 24th. Finally, Guggenheim lifted their price objective on shares of GRAIL from $75.00 to $155.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Five research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, GRAIL currently has an average rating of “Hold” and a consensus target price of $102.70.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd purchased a new stake in GRAIL in the 4th quarter valued at about $28,000. Fifth Third Bancorp boosted its stake in shares of GRAIL by 15,733.3% in the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock worth $25,000 after buying an additional 472 shares during the last quarter. Allworth Financial LP purchased a new position in shares of GRAIL in the 2nd quarter worth approximately $35,000. Geneos Wealth Management Inc. grew its holdings in shares of GRAIL by 160.0% in the first quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock valued at $30,000 after acquiring an additional 360 shares in the last quarter. Finally, Osbon Capital Management LLC purchased a new stake in shares of GRAIL during the fourth quarter valued at approximately $51,000.

About GRAIL

GRAIL, Inc is a healthcare company focused on developing blood-based technologies for the early detection of cancer. Its goal is to identify cancer signals before symptoms appear, when treatment may be more effective, by applying genomics, machine learning and other analytical methods to blood samples.

The company’s primary product is the Galleri multi-cancer early detection test, a prescription laboratory-developed test designed to screen for signals associated with multiple types of cancer from a single blood draw.